Best vitelliform macular dystrophy

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:1243OMIM:153700H35.5
Who is this for?
Show terms as
3Active trials41Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Best vitelliform macular dystrophy, also known as Best disease or Best macular dystrophy, is an inherited eye condition that affects the macula — the central part of the retina responsible for sharp, detailed vision. The disease is caused by changes (mutations) in the BEST1 gene, which provides instructions for making a protein important for the health of the retinal pigment epithelium, a layer of cells that supports the light-sensing cells in the eye. The hallmark of Best disease is the formation of a yellow, egg-yolk-like deposit (called a vitelliform lesion) beneath the macula. This deposit is made up of a fatty substance called lipofuscin. Over time, this deposit can break down and cause scarring, leading to progressive loss of central vision. Peripheral (side) vision is usually preserved. The condition typically begins in childhood, though some people may not notice symptoms until later in life. Vision loss varies widely — some individuals maintain good vision for many years, while others experience more significant decline. There is currently no cure or specific treatment that can stop or reverse Best disease. Management focuses on monitoring vision changes, using low-vision aids when needed, and in some cases treating complications such as abnormal blood vessel growth (choroidal neovascularization) with anti-VEGF injections. Regular eye exams with a retinal specialist are essential for tracking the disease and catching treatable complications early.

Also known as:

Key symptoms:

Blurred central visionDistorted vision (straight lines appear wavy)Difficulty reading or recognizing facesA yellow egg-yolk-like spot on the retina seen during eye examsGradual loss of central vision over yearsDifficulty seeing fine detailsReduced ability to see in dim lightingA dark or blank spot in the center of visionPreserved side (peripheral) visionVision that may differ between the two eyes

Clinical phenotype terms (6)— hover any for plain English
Chorioretinal scalloped atrophyHP:0001139Cystoid macular degenerationHP:0008028MetamorphopsiaHP:0012508
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

10 events
Apr 2026Comparison of the Best Method for Measuring Anti-Xa Activity in Children Receiving Unfractionated Heparin in Cardiac Intensive Care (COMPAXE-HNF)

Centre Hospitalier Universitaire de la Réunion — NA

TrialNOT YET RECRUITING
Mar 2026Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma

Canadian Cancer Trials Group — PHASE3

TrialRECRUITING
Mar 2026Clinical Trial Comparing the Efficacy of Two Teletherapy Programs at Improving Psychological Health in People With Brain Injury

Hackensack Meridian Health — NA

TrialNOT YET RECRUITING
Feb 2026AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction

Aurion Biotech — PHASE3

TrialRECRUITING
Jan 2026Wide Field OCTA in Ocular Diseases

IRCCS San Raffaele

TrialNOT YET RECRUITING
Jan 2026A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer

Shanghai Miracogen Inc. — PHASE3

TrialNOT YET RECRUITING
Nov 2025A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER

Hospital Israelita Albert Einstein — PHASE2

TrialNOT YET RECRUITING
Oct 2025Evaluating the Acceptability, Feasibility and Usability of Various Conversational Data Collection Software

AugMend Health Inc. — NA

TrialRECRUITING
Sep 2025Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)

Opus Genetics, Inc — PHASE1, PHASE2

TrialRECRUITING
Sep 2025Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

Gustave Roussy, Cancer Campus, Grand Paris — PHASE2

TrialNOT YET RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Best vitelliform macular dystrophy.

3 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

3 recruitingView all trials with filters →
Other2 trials
Study of BEST1 Vitelliform Macular Dystrophy
Actively Recruiting
PI: Stephen H Tsang, MD, PhD (Columbia University) · Sites: New York, New York; Paris +1 more
A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
Actively Recruiting
PI: Samuel Barone, MD (Nanoscope Therapeutics Inc.) · Sites: Dallas, Texas · Age: 1899 yrs

Specialists

Showing 25 of 41View all specialists →
DM
Donald Jackson Coleman, MD
Specialist
PI on 1 active trial
KF
Kaoru Fujinami
Specialist
2 Best vitelliform macular dystrophy publications
YL
Yannik Laich
Specialist
2 Best vitelliform macular dystrophy publications
AP
Adelaide Pina
Specialist
2 Best vitelliform macular dystrophy publications
LB
Lorenzo Bianco
SUMMERVILLE, SC
Specialist
3 Best vitelliform macular dystrophy publications
AA
Alessio Antropoli
Specialist
3 Best vitelliform macular dystrophy publications
AM
Alessandro Marchese
BURLINGTON, VT
Specialist
2 Best vitelliform macular dystrophy publications
AS
Andrea Saladino
Specialist
2 Best vitelliform macular dystrophy publications
TS
Tarun Sharma
Specialist
2 Best vitelliform macular dystrophy publications
ES
Edwin M Stone
IOWA CITY, IA
Specialist
3 Best vitelliform macular dystrophy publications
ES
Elliott H Sohn
IOWA CITY, IA
Specialist
3 Best vitelliform macular dystrophy publications
IH
Ian C Han
IOWA CITY, IA
Specialist
3 Best vitelliform macular dystrophy publications
AA
Alessandro Arrigo
PITTSBURGH, PA
Specialist
6 Best vitelliform macular dystrophy publications
FB
Francesco Bandello
Specialist
6 Best vitelliform macular dystrophy publications
MP
Maurizio Battaglia Parodi
Specialist
6 Best vitelliform macular dystrophy publications
EA
Emanuela Aragona
Specialist
4 Best vitelliform macular dystrophy publications
SS
Simran Singh
Birmingham, Alabama
Specialist

Rare Disease Specialist

PI on 3 active trials428 Best vitelliform macular dystrophy publications
LM
Lawrence A. Yannuzzi, MD
NEW YORK, NY
Specialist
PI on 5 active trials1 Best vitelliform macular dystrophy publication
BM
Brian P Brooks, M.D.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 8 active trials
PM
Peter A Campochiaro, MD
BALTIMORE, MD
Specialist
PI on 9 active trials
TP
Todd Durham, PhD
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Best vitelliform macular dystrophy.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Best vitelliform macular dystrophyForum →

No community posts yet. Be the first to share your experience with Best vitelliform macular dystrophy.

Start the conversation →

Latest news about Best vitelliform macular dystrophy

Disease timeline:

New recruiting trial: Medical Decision Making in Multiple System Atrophy

A new clinical trial is recruiting patients for Best vitelliform macular dystrophy

New recruiting trial: Thrombectomy Versus Best Medical Management in Large Vessel Occlusion Stroke Patients Presenting Beyond 24 Hours and With Presence of Collateral Flow on CT Angiography

A new clinical trial is recruiting patients for Best vitelliform macular dystrophy

New recruiting trial: AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction

A new clinical trial is recruiting patients for Best vitelliform macular dystrophy

New recruiting trial: OCT Guided Magmaris RMS in STEMI

A new clinical trial is recruiting patients for Best vitelliform macular dystrophy

New recruiting trial: The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program

A new clinical trial is recruiting patients for Best vitelliform macular dystrophy

New recruiting trial: ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression

A new clinical trial is recruiting patients for Best vitelliform macular dystrophy

New recruiting trial: Contingency Management as an Adjunct Treatment for Rural and Remote Disordered Gamblers

A new clinical trial is recruiting patients for Best vitelliform macular dystrophy

New recruiting trial: Preoperative Optimisation of Modifiable Risk Factors in Surgery of the Pancreas

A new clinical trial is recruiting patients for Best vitelliform macular dystrophy

New recruiting trial: A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant

A new clinical trial is recruiting patients for Best vitelliform macular dystrophy

New recruiting trial: A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

A new clinical trial is recruiting patients for Best vitelliform macular dystrophy

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What stage is the disease in right now, and what changes should I watch for?,How often should I have retinal exams to monitor for complications?,What are the signs that I should seek urgent care for my eyes?,Are there any clinical trials or gene therapy studies I might be eligible for?,Should my family members be tested for the BEST1 gene mutation?,What low-vision aids or services can help me maintain my independence?,How will this condition affect my ability to drive or work over time?

Common questions about Best vitelliform macular dystrophy

What is Best vitelliform macular dystrophy?

Best vitelliform macular dystrophy, also known as Best disease or Best macular dystrophy, is an inherited eye condition that affects the macula — the central part of the retina responsible for sharp, detailed vision. The disease is caused by changes (mutations) in the BEST1 gene, which provides instructions for making a protein important for the health of the retinal pigment epithelium, a layer of cells that supports the light-sensing cells in the eye. The hallmark of Best disease is the formation of a yellow, egg-yolk-like deposit (called a vitelliform lesion) beneath the macula. This deposi

How is Best vitelliform macular dystrophy inherited?

Best vitelliform macular dystrophy follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Best vitelliform macular dystrophy typically begin?

Typical onset of Best vitelliform macular dystrophy is childhood. Age of onset can vary across affected individuals.

Are there clinical trials for Best vitelliform macular dystrophy?

Yes — 3 recruiting clinical trials are currently listed for Best vitelliform macular dystrophy on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Best vitelliform macular dystrophy?

25 specialists and care centers treating Best vitelliform macular dystrophy are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.